Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series

PURPOSE: Monoclonal antibodies targeting interleukin-5 (IL5) and its receptor (IL5R), used for severe asthma treatment, reduce eosinophils to almost complete depletion. Fractional exhaled nitric oxide (FeNO), a surrogate marker of eosinophilic airway inflammation, is expected to decrease after their...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelletier, Geneviève, Godbout, Krystelle, Boulay, Marie-Ève, Boulet, Louis-Philippe, Morissette, Mathieu C, Côté, Andréanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126224/
https://www.ncbi.nlm.nih.gov/pubmed/35615256
http://dx.doi.org/10.2147/JAA.S358877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126224/
https://www.ncbi.nlm.nih.gov/pubmed/35615256
http://dx.doi.org/10.2147/JAA.S358877

Ejemplares similares